Search

Your search keyword '"Suradom, Chawisa"' showing total 19 results
Start Over Author "Suradom, Chawisa"
19 results on '"Suradom, Chawisa"'

15. Revised UCLA Loneliness Scale--6-Item Version

Author

Wongpakaran, Nahathai, primary, Wongpakaran, Tinakon, additional, Pinyopornpanish, Manee, additional, Simcharoen, Sutapat, additional, Suradom, Chawisa, additional, Varnado, Pairada, additional, and Kuntawong, Pimolpun, additional

Published
2020
Full Text
View/download PDF

16. Prevalence and associated factors of comorbid anxiety disorders in late-life depression: findings from geriatric tertiary outpatient settings

Author

Suradom,Chawisa, Wongpakaran,Nahathai, Wongpakaran,Tinakon, Lerttrakarnnon,Peerasak, Jiraniramai,Surin, Taemeeyapradit,Unchulee, Lertkachatarn,Surang, Arunpongpaisal,Suwanna, Suradom,Chawisa, Wongpakaran,Nahathai, Wongpakaran,Tinakon, Lerttrakarnnon,Peerasak, Jiraniramai,Surin, Taemeeyapradit,Unchulee, Lertkachatarn,Surang, and Arunpongpaisal,Suwanna

Abstract

Chawisa Suradom,1 Nahathai Wongpakaran,1 Tinakon Wongpakaran,1 Peerasak Lerttrakarnnon,2 Surin Jiraniramai,2 Unchulee Taemeeyapradit,3 Surang Lertkachatarn,4 Suwanna Arunpongpaisal5 1Geriatric Psychiatry Unit, Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 3Department of Psychiatry, Songkhla Rajanagarindra Psychiatric Hospital, Songkhla, Thailand; 4Department of Psychiatry, Prasat Neurological Institute, Bangkok, Thailand; 5Department of Psychiatry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand Purpose: The study evaluated the prevalence of comorbid anxiety disorders in late-life depression (LLD) and identified their associated factors.Patients and methods: This study involved 190 elderly Thais with depressive disorders diagnosed according to the Mini-International Neuropsychiatric Interview (MINI). Anxiety disorders were also diagnosed by the MINI. The 7-item Hamilton Depression Rating Scale (HAMD-7), Montreal Cognitive Assessment, Geriatric Depression Scale (GDS), Core Symptoms Index, Neuroticism Inventory, Perceived Stress Scale and Multidimensional Scale for Perceived Social Support were completed. Descriptive statistics and ORs were used for analysis.Results: Participants included 139 females (73.2%) with a mean age of 68.39±6.74 years. The prevalence of anxiety disorders was 7.4% for generalized anxiety disorder (GAD), 4.7% for panic disorder, 5.3% for agoraphobia, 1.1% for social phobia, 2.1% for obsessive–compulsive disorder and 3.7% for post-traumatic stress disorder, with an overall prevalence of 16.84%. The comorbidity of anxiety disorders was associated with gender (P=0.045), history of depressive disorder (P=0.040), family history of depressive disorder (P=0.004), GDS (P=0.037), HAMD-7 (P=0.001), suicidality (P=0.002) and neuroticism (P=0.003). History of alcohol use was not

Published
2019

18. Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation for prevention and treatment of perinatal depression: a systematic review and meta-analysis of randomized-controlled trials.

Author

Suradom, Chawisa, Suttajit, Sirijit, Oon-arom, Awirut, Maneeton, Benchalak, and Srisurapanont, Manit

Subjects
*UNSATURATED fatty acids, *OMEGA-3 fatty acids, *MENTAL depression, *PERINATAL period, *PRENATAL depression
Abstract

Available interventions for preventing and treating perinatal depression remain unsatisfactory. We examined the prophylactic and therapeutic effects, as well as adverse effects, of n-3 PUFA supplementation in reducing depressive symptoms during perinatal periods. We included randomized, placebo-controlled trials that reported the changes of depression severity after the perinatal participants received n-3 PUFA supplementation. After the comprehensive searches in October 2019, we selected the trials, extracted the data, and assessed the quality of included trials. We compared the standardized mean differences (SMD) of depression score changes between groups using a random-effect model. We included 11 trials in the meta-analysis and one more trial for qualitative analysis (N = 3,181). The pooled standardized mean of decreased depression scores revealed no statistically significant difference between the n-3 PUFA and the placebo groups (N = 920, SMDs = −0.05, 95% CI −0.20 to 0.10, I2 = 21%). The pooled SMDs showed no statistically significant efficacy of n-3 PUFA supplementation for prevention (N = 779, SMDs = −0.03, 95% CI −0.20 to 0.13, I2 = 24%) and treatment (N = 141, SMDs = −0.14, 95% CI −0.55 to 0.27, I2 = 31%) of perinatal depression. The efficacy of n-3 PUFA supplementation was not associated with the daily doses of DHA, EPA, or DHA plus EPA. No trial reported any serious adverse effect of n-3 PUFA supplements. Although n-3 PUFA supplementation may improve maternal and infant outcomes, our meta-analysis found insufficient evidence to determine its benefit for perinatal depression. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results